Prostaglandin F2α synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F2α-dependent and F2α-independent mechanism

Table 1 Correlation between prostaglandin F_2α synthase expression level and clinicopathological characteristics in 37 colorectal cancer patients, n (%)

Variables	No. of patients	Relatives PGFS expressions (mean ± SD)	P value
All cases	37 (100)
Gender			0.376
Male	22 (59)	1.84 ± 1.67
Female	15 (41)	1.68 ± 1.02
Age (yr)			0.495
≥ 60	19 (51)	1.40 ± 0.8
< 60	18 (49)	2.12 ± 1.8
Tumor location			0.066
Colon	15 (41)	1.71 ± 1.2
Rectum	22 (59)	1.84 ± 1.65
Differentiations			0.437
Well and Moderately	26 (70)	1.65 ± 1.29
Poorly	11 (30)	1.81 ± 1.08
T stage			0.023a
T1 or T2	25 (68)	1.26 ± 0.52
T3 or T4	12 (32)	2.47 ± 0.87
Lymph node metastasis			0.063
No	25 (68)	1.17 ± 0.56
Yes	12 (32)	2.09 ± 1.69
AJCC stage			0.069
I or II	29 (78)	1.44 ± 0.89
III or IV	8 (22)	3.09 ± 2.69

^aP < 0.05 concluded that T stage was correlated with prostaglandin F2α synthase expression level. PGFS: Prostaglandin F_2α synthase; AJCC: American Joint Committee on Cancer.

Table 2 Spearman analysis of the correlation between prostaglandin F_2α synthase expression level with clinicopathological, n (%)

Variables	No. of patients	PGFS expression level Spearman correlation	P value
T stage		0.666	0a
T1 or T2	25 (68)
T3 or T4	12 (32)
AJCC stage		0.113	0.504
I or II	29 (78)
III or IV	8 (22)

^aP < 0.05 indicates that there is a significant relationship between T stage and prostaglandin F2α synthase (PGFS) expression level in tissues. The Spearman correlation of PGFS expression level, also known as the sample correlation coefficient, was 0.666, that is, the significance relationship was moderately correlated and passed the significance test. PGFS: Prostaglandin F_2α synthase; AJCC: American Joint Committee on Cancer.